BIOVERATIV INC (NASDAQ:BIVV) Upgraded at Cowen and Company
Cowen and Company upgraded shares of BIOVERATIV INC (NASDAQ:BIVV) from a market perform rating to an outperform rating in a research note published on Monday, July 10th, Marketbeat.com reports.
BIVV has been the subject of several other reports. Argus assumed coverage on shares of BIOVERATIV INC in a research note on Friday, March 31st. They set a hold rating and a $51.00 price objective for the company. Wedbush reissued a market perform rating on shares of BIOVERATIV INC in a research report on Wednesday, June 28th. Gabelli cut shares of BIOVERATIV INC from a buy rating to a hold rating in a research report on Monday, April 24th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) cut shares of BIOVERATIV INC from a buy rating to a neutral rating and set a $55.00 price target on the stock. in a report on Monday, March 13th. Finally, Jefferies Group LLC reaffirmed a buy rating on shares of BIOVERATIV INC in a report on Friday, June 30th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $55.85.
Shares of BIOVERATIV INC (NASDAQ BIVV) traded up 0.70% during mid-day trading on Monday, reaching $63.22. 2,416,190 shares of the company’s stock traded hands. The stock has a market capitalization of $6.84 billion and a PE ratio of 15.46. The company’s 50-day moving average price is $59.79 and its 200-day moving average price is $54.74. BIOVERATIV INC has a 12-month low of $40.00 and a 12-month high of $63.48.
COPYRIGHT VIOLATION WARNING: “BIOVERATIV INC (NASDAQ:BIVV) Upgraded at Cowen and Company” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/07/23/bioverativ-inc-nasdaqbivv-raised-to-outperform-at-cowen-and-company-updated.html.
In related news, Director Louis J. Paglia purchased 2,000 shares of BIOVERATIV INC stock in a transaction dated Friday, May 26th. The stock was acquired at an average cost of $57.76 per share, with a total value of $115,520.00. Following the completion of the transaction, the director now directly owns 3,056 shares of the company’s stock, valued at $176,514.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Diantha Duvall sold 818 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $60.47, for a total transaction of $49,464.46. Following the completion of the sale, the insider now directly owns 2,128 shares of the company’s stock, valued at $128,680.16. The disclosure for this sale can be found here. Insiders bought 94,000 shares of company stock valued at $5,256,940 over the last three months.
About BIOVERATIV INC
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Stock Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related stocks with our FREE daily email newsletter.